Applied Materials forecasts a $600 million revenue hit, signaling broader disruption for the global chip industry amid escalating US-China tech tensions.
Early results for ARV-102, a novel PROTAC LRRK2 degrader, show the experimental therapy is well-tolerated and demonstrates key biomarker engagement.
Tecentriq and Zepzelca combination approved as first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC).
Precious metal outpaces gold as shrinking stockpiles and soaring industrial demand fuel a powerful market rally.
The approval of the twice-daily pill remibrutinib positions the company to challenge injectable treatments in a multi-billion dollar market.
Late-breaking trial results for obefazimod show significant efficacy, positioning the first-in-class oral therapy in a competitive market.
Shares fall despite strong Q3 sales, as expiring EV tax credits and valuation concerns spook investors.
Proposed 'OBBBA' legislation would hike tax credits for new domestic chip plants to 35%, aiming to accelerate 'Made in America' initiatives.